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Infantile hypertrophic pyloric stenosis (IHPS) has an incidence of 1–8 per 1000 live births and is inherited as a complex sex-modiﬁed
multifactorial trait with a striking male preponderance. Syndromic and monogenic forms exist, and two loci have been identiﬁed.
Infants present with vomiting due to gastric-outlet obstruction caused by hypertrophy of the smooth muscle of the pylorus. A
genome-wide SNP-based high-density linkage scan was carried out on 81 IHPS pedigrees. Nonparametric and parametric linkage analysis
identiﬁed loci on chromosomes 11q14-q22 (Zmax ¼ 3.9, p < 0.0001; HLODmax ¼ 3.4, a ¼ 0.34) and Xq23 (Zmax ¼ 4.3, p < 0.00001;
HLODmax ¼ 4.8, a ¼ 0.56). The two linked chromosomal regions each harbor functional candidate genes that are members of the ca-
nonical transient receptor potential (TRPC) family of ion channels and have a potential role in smooth-muscle control and hypertrophy.Infantile hypertrophic pyloric stenosis (IHPS [MIM
#179010]) is themost commoncause of gastrointestinal ob-
struction in theﬁrst fewmonths of life,with an incidence of
1–8 per 1000 live births in the white population.1 It typi-
cally presents in infants 2–6weeks after birthwithprojectile
vomiting, weight loss, and dehydration. Surgical treatment
by pyloromyotomy was introduced a century ago.2
A genetic predisposition to IHPS is well established. IHPS
shows familial aggregation, and the classic studies of Carter
deﬁned the disease as a paradigm for the multifactorial
sex-modiﬁed thresholdmodel of inheritance, with affected
males outnumbering females in a 4:1 ratio.3,4 This male
preponderance was conﬁrmed by later studies in various
populations.5–10 There is a striking variation in incidence
between population groups, with the cumulative incidence
inAmerican infants being 1.9 per 1000 live births inwhites,
1.8 in Hispanics, 0.7 in blacks, and 0.6 in Asians.1
In a reanalysis of data from several studies, ls (the ratio of
the disease risk among patient siblings to that among
members of the general population) was estimated to be
18.11 The same study concluded that IHPS is determined
by two or three loci of moderate effect conferring individ-
ual genotype relative risks (GRRs) of up to 5.
IHPS has also been associated with several genetic syn-
dromes, such as Cornelia de Lange12 and Smith-Lemli-
Opitz13 syndromes, and chromosomal abnormalities,
including translocation of chromosome 8 and 17 and a par-
tial trisomy of chromosome 9.14,15 Autosomal-dominant
monogenic forms of IHPShave also been reported in several
extended pedigrees.16–18
A regiononchromosome16p13-p12hasbeen identiﬁed as
theﬁrst locus formonogenic IHPS (IHPS2 [MIM#610260]).18A second locus for monogenic IHPS on chromosome 16q24
has since been identiﬁed (K.V.E., F.C., C.G., B.A.C., A.R.,
A.P., P.P., R.M.G., and E.M.K.C., unpublished data). The
gene encoding neuronal nitric oxide synthase, NOS1 (MIM
#163731), on chromosome 12q is also considered to be an
IHPS susceptibility locus (IHPS1 [MIM #179010]).19,20
Environmental factors are clearly implicated in the
development of IHPS. A period of postnatal enteral feeding
is required for the disease to develop. In addition, a recent
decline in the incidence of IHPS that parallels that of
sudden infant death has been observed, coinciding with
the implementation of the ‘‘back to sleep campaign’’21.
This has led to the suggestion that posture and feeding are
two important potentially modiﬁable environmental fac-
tors in IHPS. A further environmental factor in some cases
is erythromycin, a motilin agonist. A 7-fold increase in
the incidence of IHPS has been reported among newborn
infants who had received erythromycin for postexposure
pertussis prophylaxis.22–25 Erythromycin binds to the
motilin receptor, which is expressed in the enteric neurons
of the duodenum and colon, and induces intestinal con-
tractions.26 It is administered in low doses to improve
gastric emptying, but when used in higher doses as an
antibiotic, it can lead to prolonged contraction and hyper-
trophy.27,28
The aim of this work was the identiﬁcation of disease-
predisposing loci with a genome-wide SNP-based linkage
scan in a resource of IHPS pedigrees. A SNP-based approach
provides increased genomic coverage and a greater overall
information content in comparison to microsatellites.29,30
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Eighty-one pedigrees, all of European descent, were
ascertained from the UK and Ireland via pediatric units in
four major centers: St George’s Healthcare National Health
Service (NHS) Trust, London; Great Ormond Street Hospital
forChildrenNHSTrust, London; Barts and the LondonNHS
Trust; and Our Lady’s Children’s Hospital, Dublin. There
were a total of 302 individuals, with 206 affected. This re-
source has sufﬁcient power to detect loci of moderate effect
in a subset of these pedigrees. Thirty-nine families had two
affecteds; 25 had three affecteds; seven had four affecteds;
eighthadﬁveaffecteds; and twohad sevenaffecteds. Full de-
tails are contained in the Supplemental Data available on-
line. The ratio ofmale to female affecteds was 3 to 1. The di-
agnosis in all cases was conﬁrmed at pyloromyotomy. The
study was approved by the Ethics Committee of University
CollegeLondonHospital andbytheappropriate local insitu-
tional review boards at all other participating hospitals. In-
formedconsentwasobtained fromall participating families.
Genomic DNA was extracted from cheek swab, saliva, or
blood samples according to standard kits and protocols
(Oragene and Simhelix DNA Isolation kits). Samples were
whole-genome ampliﬂied as required with the REPLI-g
kit. Of the total 302 individuals included in the study,
whole-genome-ampliﬁed DNA was used for 182 samples.
A genome-wide scan was carried out with the Illumina
Linkage IV Panel of 6008 SNPs; 5942 SNPs (98.9%) were
successfully typed. These SNPs are designed to be evenly
distributed throughout the genomewith an average genetic
distance between SNPs of 0.64 cM and an average physical
distance of 482 kb. Fifteen whole-genome ampliﬁcation
(WGA) samples (8.2%) could not be genotyped at all;
none of the genomic DNA samples failed completely. This
genotyping was performed by Illumina, San Diego CA.
Multipoint nonparametric linkage (NPL) analysis was
performed with MERLIN 1.0.1. The Minx version of this
software was used for the analysis of the X chromosome
data.31 Thirteen of the 81 families in the resource were
excluded by the program from X chromosome analysis be-
cause no part of the pedigree was consistent with X-linked
inheritance (i.e., only male-to-male disease transmission
occurred). MERLIN 1.0.1 checks for and removes erroneous
genotypes prior to analysis. Z scores were derived at each
SNP position along with a corresponding p value. The Z
score is compared to a normal distribution to test for
deviation. The assumption of a normal distribution is con-
servative, as are the associated p values.32 Thresholds for
suggestive evidence for linkage and signiﬁcant evidence
for linkage were based on those proposed by Lander and
Kruglyak33 but are slightly less stringent. Suggestive linkage
in this study is deﬁned by a p value less than 103, and the
threshold for signiﬁcant linkage is a p value less than 104.
These values are equivalent to one-tailed Z scores of 3.1 and
3.7, respectively, which are themselves equivalent to maxi-
mized logarithm of odds (LOD) scores of 2.4 and 3.3.
The results of the multipoint NPL analysis for each chro-
mosome are shown in Figure 1. The X chromosome and
chromosome11demonstrated signiﬁcant evidence for link-Theagewith anNPLZmax of 4.3 (p< 0.00001) for theX chromo-
some and anNPLZmax of 3.9 (p< 0.00005) for chromosome
11. A comparison of Zmax scores for each family for the ‘‘crit-
ical’’ regions on chromosome 11 and the X chromosome is
given in the Supplemental Data. The critical region is arbi-
trarily deﬁned as extending to where the Z score falls below
3. This is a conservative approach to deﬁning the critical
region so that no possible candidate genes are overlooked.
Most families were consistent with linkage to either chro-
mosome 11 or the X chromosome (or both); 12 families
were not consistent with linkage to either locus. An
expanded view of each linked region is shown in Figure 2
and detailed in Tables 1 and 2. Haplotypes were derived
with the MERLIN 1.0.1 best-estimate approach, which is
based on the most likely pattern of gene ﬂow. The pedigree
structure and haplotypes for the linked regions for themost
informative families is given in the SupplementalData. Sug-
gestive evidence for linkage with a Zmax of 3.1 (p < 0.001)
was found at chromosome 22q11.1.
Parametric analysis, also with MERLIN 1.0.1, was
performed on those genomic regions that showed signiﬁ-
cant evidence for linkage with NPL analysis (chromosomes
11 and X). A disease allele frequency of 0.001 and pene-
trance of 0.6 was assumed. A heterogeneity LOD score
(HLOD) was derived at each SNP position with a corre-
sponding alpha, where a equals the proportion of families
demonstrating linkage to that locus.
Analysis of chromosome 11 with the assumption of au-
tosomal-dominant inheritance demonstrated signiﬁcant
evidence for linkage with a maximum HLOD (HLODmax)
of 3.4 (a ¼ 0.34). Analysis of the X chromosome with the
assumption of X-linked recessive inheritance also demon-
strated signiﬁcant evidence for linkage with an HLODmax
of 4.8 (a ¼ 0.56). Figure 2 shows the results of the NPL
and parametric analyses for these regions.
The genetic architecture of common familial traits that
do not segregate in a Mendelian fashion is beginning to
emerge with the increased power provided by completion
of the human-genome and HapMap projects. As antici-
pated, the genetic basis of such complex traits covers
a wide spectrum. The number of loci involved (oligo- to
polygenicity), their effect size and mode of interaction,
and the frequency and heterogeneity of causal alleles is
clearly variable.34 Linkage-analysis strategies remain a valid
approach for those traits for which there is reasonable ex-
pectation that loci of moderate effect exist, provided that
family resources adequate to offset the erosion of power
engendered by locus heterogeneity can be assembled.
Syndromic and monogenic forms of IHPS clearly exist,
but the most common form segregates as a complex multi-
factorial trait.11 The male preponderance could not be
explained solely by X-linked recessive inheritance because
male-to-male transmission is frequently observed. Two loci
for monogenic IHPS have been identiﬁed by SNP-based
genome-wide scans in two different multigeneration pedi-
grees consistent with autosomal dominant inheritance:
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Figure 1. Multipoint NPL Z Scores for All Chromosomes
Position refers to genetic distance from the telomere of the short arm of the chromosome.
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chromosome 16q24 (K.V.E., F.C., C.G., B.A.C., A.R., A.P.,
P.P., R.M.G., and E.M.K.C., unpublished data).
Suggestive evidence of linkage between IHPS and an
intragenic microsatellite polymorphism in NOS1 (MIM
#163731) on chromosome 12q24.2-q24.31 was shown
with 27 IHPS families from our resource,19 although this
ﬁnding has not been replicated.35 More recently, an associ-
ation between IHPS and a NOS1 promoter 1c regulatory
polymorphism has been reported20,36. The NOS1 gene
encodes neuronal nitric oxide synthase (nNOS), an
enzyme that catalyzes the formation of nitric oxide (NO)
in neurons of the peripheral nervous system, where it plays
a role in smooth-muscle relaxation. Transient pyloric relax-
ation is essential for the passage of stomach contents into
the small bowel, and this is mainly mediated by the action
of NO. A defect in NO production, leading to a failure of
pyloric relaxation and subsequent alteration of luminal
transit, was therefore proposed to underlie at least some
cases of IHPS. NOS1-deﬁcient mice are also reported to
have features of IHPS.36 Consequently, NOS1 is considered
to be a predisposing locus for IHPS (IHPS1 [MIM
#179010]).
Figure 2. NPL Z Score and Parametric HLOD
Plots for the Linked Regions on Chromosomes
11 and X
NPL Z score and parametric HLOD plots for chro-
mosome 11 (A) and the X chromosome (B) for
the regions showing evidence for linkage; posi-
tion refers to genetic distance from the telomere
of the short arm of the chromosome. Each marked
point corresponds to a genotyped SNP. The SNPs
flanking the critical region are labeled. Chro-
mosome 11 was analyzed under the assumption
of autosomal-dominant inheritance. Parametric
analysis of the X chromosome assumed X-linked
recessive inheritance. Both analyses assumed
a disease allele frequency of 0.001 and a reduced
penetrance of 0.6. Also shown, with red lines, are
the approximate positions of two candidate
genes, TRPC6 and TRPC5.
The statistical signiﬁcance of linkage data
generated by analysis of markers across the
entire genome remains controversial, but
thresholds adopted merely determine the
extent to which investigators wish to toler-
ate false-positive results and waste resources
in following up signals that have arisen by
chance.37,38 Nonparametric analysis was
adopted initially so that potential problems
in mis-speciﬁcation of inheritance parame-
ters could be avoided. A parametric analysis
was then carried out in those regions show-
ing signiﬁcant linkage. It can be argued that
the similar results obtained suggest that the
parameters chosen might be close to the
true pattern of inheritance at these loci.
Adopting signiﬁcance thresholds corresponding to those
proposed by Lander and Kruglyak,33 we found evidence for
signiﬁcant linkage at chromosome 11q14-q22 and Xq23,
and suggestive evidence of linkage was found at chromo-
some 22q. No evidence of linkage was obtained at the
NOS1 locus (IHPS1 [MIM #179010]) on chromosome
12q24 or at the loci for monogenic IHPS on chromosome
16. This does not of course exclude that small-effect alleles
at any of these loci might contribute to the trait in some or
even all of these pedigrees. It is consistent with the infre-
quencywithwhich loci forMendelian formsofcomplex traits
emerge as susceptibility loci for common cases. The results in
any event conﬁrm that locus heterogeneity exists for IHPS.
Linkage data from multiple small pedigrees segregating
in a non-Mendelian fashion cannot reveal unequivocal
recombinant breakpoints that allow a clear deﬁnition of
the critical linked region. On the pragmatic assumption
that the regions extend to where Z scores fall below 3.0,
a region of approximately 12 Mb on chromosome 11q14-
q22 and approximately 2 Mb on chromosome Xq23 can
be deﬁned. The former encompasses about 100 known or
predicted genes and the latter about 12 genes.
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Knowledge of the underlying pathophysiology of IHPS
is sufﬁciently advanced to allow evaluation of positional
candidate genes within the critical regions according to
their expression and putative function. Information was
collected from a number of human-genome resources
including the Ensembl, National Center for Biotechnology
Information (NCBI), and University of California-Santa
Cruz (UCSC) Browsers (genome build NCBI36.1), in
addition to the PubMed and Unigene databases.
Smooth-muscle hypertrophy in the pyloric canal under-
lies the gastric-outlet obstruction in IHPS. This develops
after birth and requires a period of enteral feeding.2 IHPS
appears to arise from a defect in gastrointestinal motility
that shows both development- and location-speciﬁc
expression, rather than a defect in the developmental
anatomy of the gastrointestinal tract. It is noteworthy
that each of these two chromosomal regions harbors
a gene from the same family of canonical transient recep-
tor potential (TRPC) cation channels: TRPC6 on chromo-
some 11q21-22 and TRPC5 on chromosome Xq23. These
genes represent the strongest functional candidate in
each region.
Mammalian TRP proteins form a superfamily of 28 genes
encoding six-transmembrane (6-TM) permeable cation-
channel subunits grouped into six subfamilies by amino
acid sequence homology. TRP channels are calcium-
permeable cation channels and appear to act as signal
integrators in a wide variety of biological contexts.39
The canonical TRP channel subfamily has seven
members. TRPC channel expression tends to be ubiquitous
and abundant in brain and neural tissues, but TRPC5 and
TRPC6 have been detected in tissues of the gut and smooth
muscle cells. TRPC6 is known to be highly expressed in
pulmonary and vascular smooth muscle, and a speciﬁc
role in regulating smooth-muscle function is emerging
for this channel.40,41 Overexpression of TRPC6 is impli-
cated in increased pulmonary smooth-muscle prolifera-
tion,42 and it is possible that there might be a similar effect
on the smooth muscle cells of the pylorus. Furthermore,
TRPC6 also acts as a sensor of membrane stretch,43 which
could be important in the gastrointestinal tract for correct
maintenance of peristalsis. TRPC6-deﬁcient mice display
increased vascular smooth muscle contractility, indicating
a role for TRPC6 in control of smooth-muscle tone.44 Gain-
of-function mutations in TRPC6 that enhance channel
activity cause a proteinuric kidney disease, focal and
segmental glomerulosclerosis (FSGS),45 but this does not
exclude quite different pathology arising from allelic vari-
ants with different functional effects.
TRPC5 is predominantly expressed in the brain, but it is
also detected in smooth muscle cells and in the stomach,
where a role in gastrointestinal-tract muscle contraction
has been proposed.46,47 There is evidence that TRPC5
might be involved in cardiac-muscle hypertrophy,48 and
it has been shown to be activated by nitric oxide,49 which
is important in smooth-muscle relaxation in the gastroin-
testinal tract.
An X-linked recessive locus accounting for a subset of
IHPS families could obviously contribute to the male
preponderance in IHPS. In our resource of familial and
sporadic cases, the ratio of males to females is more skewed
among the sporadic population (3:1 and 5:1, respectively).
It is difﬁcult to quantify the potential contribution of
X-linked recessive inheritance to male preponderance in
our limited resource. However, within the pedigrees, the
ratio of males to females is approximately 3.5:1 in families
consistent with linkage to Xq23 and 2.5:1 in families
consistent with autosomal linkage.
In conclusion, our results conﬁrm locus heterogeneity
for IHPS and identify loci on chromosomes 11q and Xq.
Strong functional candidate genes, TRPC5 and TRPC6,
exist at these loci, and further work is required for the
evaluation of their putative role by resequencing and
SNP-based association studies in our resource of IHPS
trios.






Position (cM) Z Score p Value
rs586699 91929382 94.34 2.76 0.003
rs1944108 93103823 95.35 3.22 0.0006
rs584109 93652402 95.49 3.27 0.0005
rs541821 94801223 96.72 3.9 0.00005
rs1255182 95112039 97.29 3.75 0.00009
rs483884 95551040 98.09 3.64 0.00014
rs2919032 96132850 99.45 3.6 0.0002
rs921562 96806939 100.74 3.5 0.0002
rs723513 97588753 101.04 3.49 0.0002
rs1002122 99566587 102.71 3.47 0.0003
rs622675 100165933 103.12 3.41 0.0003
rs618291 100186421 103.121 3.41 0.0003
rs1943752 100601234 103.84 3.41 0.0003
rs948734 101434119 104.05 3.49 0.0002
rs1711399 101965987 104.33 3.5 0.0002
rs1784405 101975664 104.331 3.5 0.0002
rs1276278 102028851 104.37 3.5 0.0002
rs1298740 102057989 104.38 3.5 0.0002
rs536107 102404003 104.6 3.51 0.0002
rs601535 102605727 104.72 3.47 0.0003
rs559345 102802726 104.84 3.44 0.0003
rs540819 104371671 105.69 3.04 0.0012
rs1785872 104474890 105.79 2.99 0.0014
Table 2. Linkage-Analysis Data for the Critical Region





Position (cM) Z Score p Value
rs2016878 109820582 105.91 2.91 0.002
rs1890141 110232670 106.32 4.18 0.00001
rs926412 110380673 106.47 4.19 0.00001
rs1016231 110619665 106.71 4.22 0.00001
rs3027802 110894171 106.99 4.26 0.00001
rs7049660 111445482 107.63 3.43 0.0003
rs2040497 111642086 108.3 2.85 0.002
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Two ﬁgures and one table are available at http://www.ajhg.org/.
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